Skip to main content
Download PDF

Comprehensive analyses reveal the carcinogenic and immunological roles of ANLN in human cancers

Cancer Cell International volume 22, Article number: 188 (2022) Cite this article

Abstract

Background

Anillin (ANLN) is an actin-binding protein that is essential for cell division and contributes to cell growth and migration. Although previous studies have shown that ANLN is related to carcinogenesis, no pan-cancer analyses of ANLN have been reported. Accordingly, in this study, we evaluated the carcinogenic roles of ANLN in various cancer types using online databases.

Methods

We evaluated the potential carcinogenic roles of ANLN using TIMER2 and Gene Expression Omnibus databases with 33 types of cancers. We further investigated the associations of ANLN with patient prognosis, genetic alterations, phosphorylation levels, and immune infiltration in multiple cancers using GEPIA2, cBioPortal, UACLAN, and TIMER2 databases. Additionally, the potential functions of ANLN were explored using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. Reverse transcription quantitative polymerase chain reaction and immunohistochemistry were used to determine ANLN mRNA and protein expression in colorectal cancer (CRC), gastric cancer (GC), and hepatocellular carcinoma (HCC) cell lines.

Results

ANLN was overexpressed in various tumor tissues compared with corresponding normal tissues, and significant correlations between ANLN expression and patient prognosis, genetic alterations, phosphorylation levels, and immune infiltration were noted. Moreover, enrichment analysis suggested that ANLN functionally affected endocytosis, regulation of actin cytoskeleton, and oxytocin signaling pathways. Importantly, ANLN mRNA and protein expression levels were upregulated in gastrointestinal cancers, including CRC, GC, and HCC.

Conclusions

Our findings suggested that ANLN participated in tumorigenesis and cancer progression and may have applications as a promising biomarker of immune infiltration and prognosis in various cancers.

Background

With rapid increases in global warming and unhealthy lifestyles, cancer has become a major threat to public health worldwide [1]. Oncogenes are genes that promote the neoplastic transformation of cells [2]; accordingly, oncogenes are often highly expressed in various cancers, and cancer can result in the abnormal expression of many oncogenes [3]. Therefore, analysis of oncogene expression may facilitate the identification of cancer and cancer-related mechanisms and to determine patient prognosis. For example, CD96 mediates various immune responses and is associated with immune cell infiltration and prognosis in patients with melanoma and glioma [4]. The identification of oncogenes has been accelerated by developments in sequencing technology; a growing number of genome-wide datasets are available in public platforms, such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases [5, 6].

As a critical factor involved in cell division, anillin (ANLN) is an actin-binding protein that contributes to cell growth and migration [7]. The localization of ANLN varies as the cell cycle progression; ANLN is mainly localized in the nucleus during interphase and in the cell cortex during mitosis [8]. Notably, ANLN is involved in the occurrence and progression of breast cancer [9] and pancreatic cancer [10], and overexpression of ANLN mRNA and protein is associated with poor survival [11]. Moreover, Jia et al. reported that ANLN may be a therapeutic target in patients with hepatocellular carcinoma HCC owing to its effects on carcinogenesis in HCC cell lines [12]. Although the biological functions of ANLN have been extensively studied, few comprehensive analyses have examined the specific roles of ANLN in various cancers.

Accordingly, in this study, we conducted a pan-cancer analysis of ANLN using TCGA and GEO databases. Subsequently, we systematically explored the relationships of ANLN expression with patient prognosis, genetic alterations, phosphorylation, the immune microenvironment, and gene function in order to uncover the molecular mechanisms of ANLN in cancer. Finally, we verified the upregulation of ANLN in gastrointestinal malignancies.

Materials and methods

Analysis of gene expression

The Human Protein Atlas (HPA) database, which includes distribution information for 26,000 types of tissues and cells, was applied to investigate ANLN protein expression (https://www.proteinatlas.org/) [13]. The TIMER2 database, a comprehensive analysis network tool was used to explored ANLN expression from TCGA database and the immune microenvironment with the “Gene_DE” module in tumors and corresponding normal tissues [14].

Based on RNA-sequencing expression data, the Gene Expression Profiling Interactive Analysis (GEPIA2) database was applied to investigate tumors without a control group in the TIMER2 database (http://gepia.cancer-pku.cn/#analysis) [15]. Additionally, the “Expression analysis-BoxPlot” module was used to investigate ANLN expression in tumors and normal tissues based on the following criteria: P ≤ 0.01, log2|fold change| (FC) = 1. We utilized the “Pathological Stage Plot” module to assess correlations between ANLN expression and clinicopathological stage through transforming the log2([transcripts per million] + 1). Additionally, CPTAC in the UALCA database was employed to investigate total protein and phosphoprotein expression by searching ANLN in tumor and corresponding normal tissues (http://ualcan.path.uab.edu/analysis-prot.html) [16]. The Oncomine database, a platform based on microarray data, was employed to conduct a meta-analysis of ANLN expression in some types of cancer, using the following parameters: P ≤ 0.05, log2|FC|= 1.5. The results are presented as medians and P values of medians for each type of cancer.

Analysis of survival prognosis

The association of ANLN expression with overall survival (OS) and disease-free survival (DFS) was determined using the “Survival Map” module of GEPIA2 in different cancers from TCGA datasets. The thresholds for the low- and high-expressoin groups were set to cut-off-low (50%) and cut-off-high (50%) values, respectively, and log-rank tests were used to validate our hypotheses. The “Survival Analysis” module was used to generate survival plots in GEPIA2.

Kaplan–Meier plotter is a tool that uses different GEO databases for the analysis of OS, distant metastasis-free survival (DMFS), progression-free survival (PFS), relapse-free survival (RFS), first progression (FP), disease-specific survival, and post-progression survival (PPS) [17]. Kaplan–Meier survival plots were generated using 95% confidence intervals, “autoselect best cutoff”, and log-rank P values.

Analysis of genetic alteration

Using the cBioPortal website (https://www.cbioportal.org/), we applied the “TCGA Pan Cancer Atlas Studies” module to investigate genetic alterations in ANLN [18]. We used the “Mutations” module to explore the mutation site information for the ANLN gene. Furthermore, we also obtained data on OS, RFS, PFS, and DFS to assess the effects of ANLN genetic alterations using the “comparison” module. Kaplan–Meier plots are presented using log-rank P values.

Analysis of phosphorylation

The ID “ANLN_HUMAN” was entered in the SMART database to obtain ANLN protein domains and phosphorylation sites (http://smart.embl-heidelberg.de/smart/). We then further analyzed phosphorylation sites and ANLN protein expression in different cancers using data from the UACLAN database. The standard deviation between the tumor sample and the median was represented by the z-value.

Analysis of the tumor immune microenvironment

The “immune gene” module of TIMER2 was used to investigate the association between ANLN expression and immune cells, including CD4+ T cells, CD8+ T cells, B cells, macrophages, neutrophils, natural killer (NK) cells, and cancer-associated fibroblasts, in different types of tumors. P values and partial correlation values were obtained using Spearman rank correlation tests with purity adjustment. Student’s t tests were applied for comparisons between two groups, and analysis of variance was used for comparisons of more than two groups. Pearson’s correlations were used to detect the strength of differences between certain variables.

Analysis of ANLN-related gene enrichment

The STRING website was used with the following thresholds: protein name, “ANLN”; and organism, “Homo sapiens” (https://string-db.org/). The following primary threshold values were set: minimum required interaction score, “low confidence (0.150)”; meaning of the network edge, “evidence”; maximum number of interaction objects to display, “no more than 50 in the first shell”; and source of active interaction, “experiment”. We then downloaded 50 ANLN-binding proteins verified by experiments.

Next, the “Similar Gene Detection” module from the GEPIA2 database was used to obtain the top 100 ANLN-related genes. Pearson correlation analysis was applied to evaluated associations between ANLN and selected genes in the “correlation analysis” module. Furthermore, the ‘Gene_Corr’ module of TIMER2 was used to generate a heatmap for the above genes.

Intersection analysis of ANLN-binding and interacting genes was then performed using the Venn diagram viewer Jvenn [19]. We combined the above two cohorts of data for the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis with the following parameters in the DAVID database: identifier, “OFFICIAL_GENE_SYMBOL”; and species, “Homo sapiens”. Visualization was performed using the R packages “tidyr” and “ggplot2”. Finally, the R package “clusterProfiler” was applied for Gene Ontology (GO) enrichment analysis. Data for molecular functions were visualized as cnetplots, with the following parameters: circular = F, colorEdge = T, node_label = T. In two-tailed tests, P values less than 0.05 were considered statistically significant.

Cell culture

HCT116 and SW480 human colorectal cancer (CRC) cells and NCM460 human normal colonic epithelial cells were purchased from Cell Bank (Shanghai, China) and Procell Life Science (Wuhan, China), respectively. AGS and 7901 human gastric cancer (GC) cells, GES human gastric mucosa epithelial cells, HepG2 and Huh human HCC cells, and LO2 human liver cells were obtained from the Central Laboratory of the First Hospital Affiliated to Anhui Medical University. Cells were cultured in Dulbecco’s modified Eagle’s medium (HyClone) containing 10% fetal bovine serum (VivaCell, Shanghai, China). The cells were incubated at 37 °C in a cell culture incubator with an atmosphere containing 5% CO2.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from cells using TRIzol reagent (Takara, Shiga, Japan). Reverse transcription of cDNA was performed using a Primescript rt kit (Takara) with the following protocol: 37 °C for 15 min, 85 °C for 5 s, and 4 °C for 2 min. ANLN expression levels were evaluated by qPCR using SYBR Green qPCR Mix (Takara) with the following protocol: predenaturation at 95 °C for 30 s, 40 cycles of denaturation at 95 °C for 5 s and annealing and extension at 65 °C for 30 s, 95 °C for 10 s, and 65 °C for 5 s. The following primers used were: GAPDH forward, 5′-CTCACCGGATGCACCAATGTT-3′ and GAPDH reverse, 5′-CGCGTTGCTCACAATGTTCAT-3′; ANLN forward, 5′-CAAGATGTATCCAATGACT-3′ and ANLN reverse, 5′-TGACTGAAGAATGAATGTT-3′. The relative expression of ANLN was determined using the 2−ΔΔCt method.

Immunohistochemistry of validation

We explored the protein expression of ANLN in gastrointestinal tumors and corresponding normal tissues in “tissue” and “pathology” of modules. All images from immunohistochemical experiments were obtained from the HPA database, and specific patient information was listed. Regents: Antibody HPA005680 (Atlas Antibodies Cat#HPA005680, RRID: AB_2667388) (1:100); Antibody HPA050556 (Atlas Antibodies Cat#HPA050556, RRID: AB_2681175) (1:450); Antibody CAB033902 (Santa Cruz Biotechnology Cat#sc-67327, RRID: AB_2058302) (1:125); Antibody CAB062547 (Atlas Antibodies Cat#AMAb90660, RRID: AB_2665622) (1:100).

Statistical analysis

Student’s t tests were used to assess ANLN gene expression data obtained from the TIMER, GEPIA, and Oncomine databases. The prognostic roles of ANLN were estimated using GEPIA and Kaplan–Meier plotter. Hazard ratios and P values or log-rank P values were used for comparing OS, RFS, DFS, and DMFS in high- and low-risk groups or altered and unaltered groups. Correlations between ANLN expression and immune infiltration were analyzed using Spearman’s analysis. Differences in ANLN expression between two groups and among multiple groups were analyzed using Student’s t tests and analysis of variance, respectively. Results with P values less than 0.05 were considered statistically significant.

Results

ANLN expression profiles in normal and tumor tissues

As shown in Fig. 1A and B, ANLN protein was highly expressed in testis and bone marrow tissues, and immunohistochemical analyses obtained from the HPA database suggested that ANLN protein was primarily localized in the cell nucleus. Further analysis of ANLN expression in the TIMER2 database (Fig. 1C) showed that ANLN was upregulated in breast carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), cholangiocarcinoma, head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA), lung squamous cell carcinoma, kidney renal clear cell carcinoma (KIRC), liver HCC (LIHC), rectum adenocarcinoma, lung adenocarcinoma (LUAD), thyroid carcinoma (THCA), stomach adenocarcinoma (STAD), uterine corpus endometrial carcinoma (UCEC; P < 0.001), pancreatic adenocarcinoma (PRAD), cervical squamous cell carcinoma and endocervical adenocarcinoma, skin cutaneous melanoma (SKCM), pheochromocytoma and paraganglioma (P < 0.01), and pancreatic adenocarcinoma (PAAD; P < 0.05).

Fig. 1
figure 1

ANLN expression and its correlation with clinicopathological features. A The expression of ANLN mRNA in human normal testis tissues. B The expression of ANLN mRNA in human normal bone marrow tissues. C Analysis ANLN expression in various tumors or certain tumor subtypes in TIMER2 database. D Analysis of ACC, DLBC, LAML, LGG, OV, SARC, TGCT, and UCS expression between TCGA tumor tissues and GTEx database the corresponding normal tissues. E Analysis of ANLN total protein expression between breast cancer, clear cell RCC, colon cancer, ovarian cancer, LUAD, UCEC and corresponding normal tissues in CPTAC dataset. F Analysis of ANLN in pathological stages of ACC, BLCA, CESC, COAD, KICH, LUAD, PAAD, THCA. *P < 0.05; **P < 0.01; ***P < 0.001; Log scale adopts Log2 (TPM + 1)

Full size image

Because of a lack of some types of normal tissues in TIMER2 database, we further evaluated ANLN expression in the GTEx database using GEPIA2. The results suggested that ANLN expression in cancer tissues exceeded that in corresponding normal tissues for lymphoid neoplasm diffuse large B-cell lymphoma, brain lower grade glioma (LGG), thymoma (THYM), skin cutaneous melanoma (SKCM), and testicular germ cell tumors (TGCTs). There were no significant differences between tumor and normal tissues for acute myeloid leukemia, kidney chromophobe (KICH), sarcoma, or glioblastoma multiforme (GBM; P > 0.05; Fig. 1D).

Total ANLN protein was evaluated using CPTAC datasets; the findings suggested that ANLN was upregulated in BLCA, ovarian cancer, COAD, LUAD, KIRC, and UCEC (P < 0.05; Fig. 1E). Furthermore, meta-analysis results confirmed that ANLN was overexpressed in cervical cancer, HNSC, CRC, BLCA, and STAD in the Oncomine database (P < 0.05; Additional file 1: Figure S1A–E).

To further investigate ANLN expression, we evaluated the association between ANLN expression and pathological tumor stage using the “Stage Plot” module in GEPIA2. The results showed that ANLN expression was associated with pathological tumor stage in ACC, BLCA, BRCA, KICH, KIRP, LUAD, KIRC, LIHC, and UCS (P < 0.05), but not in other tumor types (Fig. 1F; Additional file 2: Figure S2A–D).

Analysis of the prognostic value of ANLN

Based on our findings regarding the expression of ANLN in different cancer types, patients were segmented into high and low expression groups to investigate the correlation of ANLN expression with prognosis. As shown in Fig. 3A and B, patients with low expression had longer OS and DFS than those with high expression in ACC (P = 8.3e-05; P = 0.0033), BLCA (P = 0.034; P = 0.026), KIRC (P = 0.0021; P = 0.018), KIRP (P = 0.00059; P = 0.00049), LIHC (P = 0.00085; P = 0.00046), LUAD (P = 2.6e-06; P = 0.0043), MESO (P = 7.8e-07; P = 0.0089), PAAD (P = 0.013; P = 3e-04), and UVM (P = 0.041; P = 0.037), suggesting that low ANLN expression was associated with better prognosis. By contrast, in THYM, ANLN upregulation was correlated with longer OS (P = 0.0085), but not with DFS (P = 0.47; Fig. 2A and B; Additional file 3: Figure S3A and B).

Fig. 2
figure 2

The correlation analysis between ANLN expression and prognosis of cancers in TCGA database using GEPIA2. A Overall survival. B Disease-free survival. The survival map with positive results were presented

Full size image

Notably, in patients with breast cancer, low ANLN expression was correlated with better DMFS (P = 3.9e-07), RFS (P = 3.6e-10), and OS (P = 0.027), as demonstrated using Kaplan–Meier plotter (Fig. 3A). By contrast, high ANLN expression was related to better OS (P = 0.00027), FP (P = 0.017), and PPS (P = 2.1e−08) in patients with GC (Fig. 3B). The opposite results were observed for OS (P < 0.0001) and FP (P = 3.6e−09) in patients with lung cancer (Fig. 3C). In ovarian cancer, high expression ANLN was associated with poor OS (P = 0.00038) and PPF (P = 0.01; Fig. 3D). Moreover, ANLN expression level was significantly correlated with OS (P = 2.6e−05), DFS (P = 8.7e−06), RFS (P = 3.6e−06), and PPS (P = 5.2e−08) in patients with liver cancer (Fig. 3E). Overall, these findings showed that ANLN expression was associated with prognosis in various types of tumors and that high ANLN expression was associated with poor prognosis in most cancers.

Fig. 3
figure 3

The correlation between ANLN expression and prognosis of certain cancers using the Kaplan–Meier plotter containing OS, RFS, PFS, PPS, DMFS, FP, and DFS. A Breast cancer. B Gastric cancer. C Lung cancer. D Ovarian cancer. E Liver cancer

Full size image

Genetic alterations in ANLN

Next, the cBioPortal database was used to investigate genetic alterations in ANLN in various types of tumors. We found that the frequency of ANLN alterations was the most common in UCEC (mutated in 7.18% of cases), followed by skin cutaneous melanoma (4.95%). In esophageal adenocarcinoma, 3.3% of cases showed amplification, and amplification was the only alteration type observed in all cases of pheochromocytoma and paraganglioma (Fig. 4A). Moreover, in bladder urothelial carcinoma and LUAD, alterations observed in TCGA datasets included mutations, amplifications, multiple alterations, deep deletions, and structural variants; missense mutations were the main types of ANLN mutations (Fig. 4B). Among 181 mutants, R153Q/L mutation was detected in five cases (uterine serous carcinoma, LUAD, cutaneous melanoma, mucinous adenocarcinoma of the colon and rectum, and HNSC) and induced a frame-shift mutation in ANLN, resulting in truncation of the protein (Fig. 4C). No three-dimensional structure in the ANLN protein was detected at the mutation site (amino acid 153). We then analyzed the association between ANLN genetic alterations and patient prognosis. In patients with UCEC, patients with alterations in ANLN showed improved OS (P = 0.0297), but not DSF (P = 0.197), DFS (P = 0.411), or PFS (P = 0.121) in comparison with patients harboring wild-type ANLN (Fig. 4C). By contrast, in patients with LUAD, those without ANLN modifications had longer PFS (P = 0.0218) and DFS (P = 2.544e-6) than those with ANLN alterations, although no changes in OS (P = 0.523) or DSF (P = 0.288) were observed.

Fig. 4
figure 4

Analysis of ANLN genetic alteration of TCGA cancers the cBioPortal database. A The alteration frequency with mutation type. B The alteration frequency with mutation site. C The correlation between alteration status and prognosis in UCEC and LUNG

Full size image

Phosphorylation of ANLN

We then identified significantly different phosphorylation sites in ANLN protein (Fig. 5A) and assessed differences in the phosphorylation levels of ANLN between normal and tumor tissues using the CPTAC database for patients with BLCA, CRC, LUAD, UCEC, and ovarian cancer. Many phosphorylation sites were found to contribute to tumor development and progression. The phosphorylation of ANLN protein was increased at phosphorylation site S182 in LUAD and UCEC and at S485 in ovarian cancer and UCEC (Fig. 5B). Furthermore, many phosphorylation sites showed enhanced phosphorylation in BLCA, including S67, T272, and S800, whereas phosphorylation at S102 decreased (Fig. 5C). In LUAD, CRC, and ovarian cancer, ANLN showed increased phosphorylation at S225, S755, S792, and S518 (Fig. 5D). Furthermore, data from the PhosphoNET database indicated that ANLN phosphorylation at S102, S182, S485, and S518 has been experimentally confirmed [20,21,22,23] (Table 1). Further molecular analyses are required to assess the specific mechanisms through which phosphorylation contributes to tumorigenesis.

Fig. 5
figure 5

Analysis of ANLN protein phosphorylation in cancers using CPTAC of UACLAN database. A Phosphorylation sites with significant differences are marked in ANLN protein (NP_061155.2, S6, S102, S182, S225, S272, S485, S518, S562, S664, S755, S792, S800 sites). B Expression of different ANLN protein phosphorylation sites in breast cancer. C Expression of ANLN protein phosphorylation sites S182 and S485 in LUAD, ovarian cancer and UCEC. D Expression of ANLN phosphorylation sites S225, S755, S792 and S518 in cancers

Full size image
Table 1 Analysis of CPTAC-identified phosphorylation sites of ANLN via the PhosphoNET database
Full size table

Relationship between immune infiltration and ANLN

The tumor microenvironment consists mainly of a mixture of tumor cells and stromal components and is strongly associated with tumorigenesis, invasion, and metastasis [24, 25]. Hence, we next examined whether ANLN expression was related to the tumor microenvironment in various types of cancer by assessing changes in CD8+ T cells, CD4+ T cells, B cells, NK cells, neutrophils, and macrophage in samples showing variations in ANLN expression in the TIMER, MCPCOUNTER, and TIDE databases. Overall, the expression of ANLN was found to be associated with the infiltration levels of CD8+ T cells in 13 tumor types, CD4+ T cells in 20 tumor types, B cells in 20 tumor types, macrophages in 20 tumor types, neutrophils in 26 tumor types, and NK cells in 15 tumor types (Fig. 6A–F, Additional file 4: Figure S4, Additional file 5: Figure S5, Additional file 6: Figure S6). Furthermore, ANLN expression was positively associated with immune infiltration of CD8+ T cells, neutrophils, and macrophages, but negatively associated with CD4+ T cells in BCLA, LGG, PAAD, and SKCM. NK cells were negatively correlated with ANLN expression in HNSC, KICH, and TGCT, and B cells were negatively correlated with ANLN expression in ESCA, HNSC, and LUAD. The results also suggested that ANLN expression was highly correlated with immune infiltration in LIHC; indeed, in LIHC, ANLN expression was positively correlated with tumor purity, CD8+ T cells, CD4+ T cells, B cells, neutrophils, and macrophages and negatively correlated with NK cells (P < 0.05).

Fig. 6
figure 6

Analysis of the correlation between ANLN expression and immune cells. A CD4+T cells. B CD8+T cells. C Macrophage. D NK cells. E B cells. F Neutrophils

Full size image

Cancer-associated fibroblasts are pivotal components of the tumor stroma and participate in modulating tumor-infiltrating immune cells [26]. Importantly, we demonstrated that ANLN expression was positively correlated with cancer-associated fibroblasts in BLCA, BRCA-LumA, ESCA, HNSC, human papillomavirus-negative HNSC, KIRC, KIRP, LUAD, MESO, SKCM, metastatic SKCM, THCA, and USC, but negatively correlated with BRCA and TCGT (Fig. 7A and B).

Fig. 7
figure 7

Analysis of the correlation between ANLN expression and immune cell infiltration of cancer-associated fibroblasts in cancers. A The heatmap of all tumors in TCGA generated by EPIC, MCPCUNTER, and TIDE algorithm. B The scatter plots of cancers generated by one algorithm, including BLCA, BLCA-LumA, ESCA, HNSC, LUAD, HNSC-HPV-, TGCT, and MESO

Full size image

Enrichment of ANLN-related genes

We screened out ANLN-binding proteins and ANLN co-expression genes for pathway enrichment analyses to elucidate the molecular mechanisms through which ANLN may contribute to cancer occurrence and progression. As shown in Fig. 8A, we acquired 50 experimentally verified ANLN-binding proteins and their interaction networks using the STRING tool. Then, based on tumor expression data from TCGA in GEPIA2, we performed correlation analysis to investigate the top 100 ANLN co-expression genes. As shown in Fig. 8B, ANLN expression was positively correlated with G protein-coupled receptor 62 (GPR62; R = 0.38), myelin-associated glycoprotein (MAG; R = 0.35), proteolipid protein 1 (PLP1; R = 0.4), Rac GTPase activating protein 1 (RACGAP1; R = 0.6), and transmembrane protein 144 (TMEM144; R = 0.36; all P < 0.001). Moreover, heatmap analysis also showed that these genes were positively correlated with ANLN expression in various cancers, including GBM and LGG (Fig. 8C). Further analyses showed that RACGAP1 was identified as both an ANLN-binding protein and ANLN co-expression gene (Fig. 8D).

Fig. 8
figure 8

Enrichment analysis ANLN-related genes. A The interaction network of 50 ANLN-binding proteins with available experimentally evidenced in the STING. B The correlation between ANLN and selected genes, including GPR62, PLP1, MAG, TMEM144, RAGGCP1 using GEPIA2. C The corresponding heatmap in the all cancers are presented. D Venn diagram of the ANLN-binding and related genes. E Analysis of KEGG pathway. F The cnetplot for the molecular function based on GO analysis

Full size image

We then conducted KEGG and GO enrichment analyses for ANLN. KEGG enrichment analyses indicated that the role of ANLN in tumorigenesis was associated with genes involved in endocytosis, bacterial invasion of epithelial cells, regulation of the actin cytoskeleton, and the oxytocin signaling pathway (Fig. 8E). Notably, however, most genes associated with the role of ANLN in tumor progression were related to cellular biology or the microstructure of actin, such as actin binding, actin filament binding, motor activity, ATPase activity, and structural constituents of the cytoskeleton (Fig. 8F).

Verification the expression of ANLN in gastrointestinal cancers

Next, we assessed the expression of ANLN mRNA in HCC, GC, and CRC cell lines using RT-qPCR. The results suggested that ANLN mRNA expression was higher in HepG2 HCC cells, 7901 and AGS GC cells, and HCT116 and SW480 CRC cells than in LO2 normal hepatic epithelial cells, GES gastric epithelial cells, and NCM460 colon epithelial cells, respectively (Fig. 9A–C). Additionally, we further confirmed the protein expression of ANLN in gastrointestinal tumors using immunohistochemistry data from the HPA database. In comparison with corresponding normal tissues, ANLN was upregulated in HCC, GC, CRC, and pancreatic cancer tissues (Fig. 9D–G). The expression of ANLN protein was predominately localized in the nucleus in GC and CRC and in the cytoplasm and membrane in HCC and pancreatic cancer.

Fig. 9
figure 9

Validation of ANLN mRNA and protein expression in gastrointestinal malignancies. A–C qRT-PCR analysis detected the ANLN mRNA expression relative to GAPDH in colorectal cancer, gastric cancer, and hepatocellular carcinoma cell lines. D–G The Human Protein Atlas database validated the ANLN protein expression in liver cancer, colorectal cancer, stomach cancer, pancreatic cancer and corresponding normal tissues. *P < 0.05

Full size image

Discussion

Cancer is a major threat to human health, and studies are urgently needed to identify potential prognostic biomarkers and explore the mechanisms of cancer occurrence and progression. Although ANLN is highly expressed in normal testis and bone marrow, abnormal expression of ANLN has not been found in diseases related to these organs. Many studies have shown that ANLN protein affects various cellular processes, such as cytokinesis, cell cycle, podocyte cell adhesion, and motility [7, 27, 28]. Moreover, ANLN has been shown to have roles in carcinogenesis. For example, ANLN silencing using lentivirus transfection inhibits proliferation, migration, and cell cycle progression in breast cancer cells [29]. However, no pan-cancer analyses of ANLN in various types of tumors has been reported, and it is unclear whether ANLN has critical roles in multiple types of cancer through a common molecular mechanism.

In this study, we found that ANLN was overexpressed in most types of tumors compared with corresponding normal tissues. Furthermore, ANLN expression was found to be associated with pathological stage in ACC, BLCA, BRCA, KICH, KIRC, KIRP, LIHC, LUAD, and UCS, and survival analysis indicated that ANLN upregulation was correlated with poor prognosis in ACC and LIHC. ANLN overexpression in THYM was associated with better OS, but poorer RFS. Overall, ANLN expression was associated with poor prognosis in most types of cancer. However, high ANLN expression was associated with better prognosis in GC; this result may be related to the unique pathological features of GC. Indeed, in a previous study, ANLN was shown to be overexpressed in proliferative gastric tumors compared with aggressive and metabolic gastric tumors [30].

Genetic mutations play essential roles in cancer metastasis and recurrence [31, 32]. In breast cancer, different genetic mutations are associated with specific metastasis sites, and these mutations may therefore represent biomarkers or therapeutic targets in patients with metastatic breast cancer [33]. In this study, our results showed that alterations in ANLN were most common in uterine cancer, followed by bladder cancer, UCEC, and SKCM. Moreover, ANLN alterations could be protective in UCEC, whereas ANLN mutations were associated with shorter RFS and PFS, but not OS, in patients with LUAD. Therefore, as an oncogene, ANLN may be a prognostic factor in multiple types of tumors.

The tumor immune microenvironment extensively influences the migration, invasion, and metastasis of various types of cancer cells [34, 35], and immunotherapy has recently been shown to have important roles in the management of patients with cancer by inhibiting the tumor immune microenvironment and thereby exerting antitumor immune activity [36, 37]. In our study, ANLN expression was correlated with CD8+ T cells, neutrophils, and macrophages in BLCA, LIHC, KIRP, PRAD, and HNSC. As a vital component of stromal cells, cancer-associated fibroblasts are associated with disease recurrence and chemotherapy resistance in several types of cancer [38]. We found that ANLN expression was associated with cancer-associated fibroblasts in most tumor types. Combined with the results of survival analyses, our findings confirmed that cancer-associated fibroblasts were associated with a poor prognosis in many cancer types, including LIHC and KICH. A previous study also revealed that stromal gene expression was related to a poor prognosis in patients with CRC [39]. Overall, our results indicated that aberrant ANLN expression could alter tumor immunity. Further studies are needed to fully elucidate the molecular mechanisms through which ANLN exerts these effects.

We also evaluated ANLN-binding proteins and co-expressed genes. Our results showed that ANLN-related genes were primarily associated with cytokinesis, cell movement, and cell signaling, consistent with previous studies. Furthermore, we found that ANLN interacted with GPR62, MAG, PLP1, RACGAP1, and TMEM144; RACGAP1 expression was particularly associated with ANLN expression. These glycoprotein-related genes are mainly involved in the regulation of cellular physiological processes [40,41,42,43]. Furthermore, RACGAP1 plays key roles in several cellular processes, including differentiation and migration, and its expression is strongly correlated with advanced-stage tumors [44,45,46]. These results from enrichment analysis established a basis for further exploration of the functions and regulatory mechanisms of ANLN.

There were several limitations to this study. First, the limited number of samples from individual tumors may have led to inaccurate results. Second, we only verified ANLN expression in gastrointestinal cancers, and the functions of ANLN in vivo and in vitro still need to be clarified. Third, more work is needed to evaluate the effects of ANLN on promoting tumor occurrence and progression.

Conclusion

In conclusion, our results showed that ANLN expression was increased in various types of tumors and that ANLN expression was correlated with prognosis, suggesting that ANLN may be a prognostic indicator for certain cancers, particularly LIHC. Moreover, we further identified the potential molecular mechanisms through which ANLN may modulate immune infiltration, cell division, and cell the cycle. Further studies are needed to validate the potential applications of ANLN in the diagnosis and treatment of cancers.

Availability of data and materials

The datasets obtained and explored in this study are available in the GEPIA2, UACLAN, HPA and TIMER2 databases.

Abbreviations

TCGA:

The Cancer Genome Atlas

GEO:

Gene Expression Omnibus

ANLN:

Anillin

HPA:

Human Protein Atlas

GEPIA2:

Gene Expression Profiling Interactive Analysis

FC:

Fold change

OS:

Overall survival

DFS:

Disease-free survival

DMFS:

Distant metastasis-free survival

PFS:

Progression-free survival

RFS:

Relapse-free survival

FP:

First progression

PPS:

Post-progression survival

KEGG:

Kyoto Encyclopedia of Genes and Genomes

GO:

Gene Ontology

BLCA:

Breast carcinoma

BRCA:

Breast invasive carcinoma

COAD:

Colon adenocarcinoma

HNSC:

Head and neck squamous cell carcinoma

KIRP:

Kidney renal papillary cell carcinoma

ESCA:

Esophageal carcinoma

KIRC:

Kidney renal clear cell carcinoma

LIHC:

Liver hepatocellular carcinoma

LUAD:

Lung adenocarcinoma

THCA:

Thyroid carcinoma

STAD:

Stomach adenocarcinoma

UCEC:

Uterine corpus endometrial carcinoma

PRAD:

Pancreatic adenocarcinoma

SKCM:

Skin cutaneous melanoma

LGG:

Lower grade glioma

THYM:

Thymoma

TGCT:

Testicular germ cell tumor

KICH:

Kidney chromophobe

GBM:

Glioblastoma multiforme

GPR62:

G protein-coupled receptor 62

MAG:

Myelin-associated glycoprotein

PLP1:

Proteolipid protein 1

RACGAP1:

Rac GTPase activating protein 1

TMEM144:

Transmembrane protein 144

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca-Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  PubMed  Google Scholar 

  2. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med. 2011;3(11):623–36. https://doi.org/10.1002/emmm.201100176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y, Su C, Zhang W, Sun X, He J, et al. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics. 2020;112(6):3958–67. https://doi.org/10.1016/j.ygeno.2020.06.044.

    Article  CAS  PubMed  Google Scholar 

  4. Ye W, Luo C, Liu F, Liu Z, Chen F. CD96 Correlates with Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis. Front Radiat Oncol. 2021;11:634617. https://doi.org/10.3389/fonc.2021.634617.

    Article  Google Scholar 

  5. Blum A, Wang P. Zenklusen JC: SnapShot: TCGA-Analyzed Tumors. Cell. 2018;173(2):530. https://doi.org/10.1016/j.cell.2018.03.059.

    Article  CAS  PubMed  Google Scholar 

  6. Sang C, Chao C, Wang M, Zhang Y, Luo G, Zhang X. Identification and validation of hub microRNAs dysregulated in esophageal squamous cell carcinoma. Aging. 2020;12(10):9807–24. https://doi.org/10.18632/aging.103245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hall G, Lane BM, Khan K, Pediaditakis I, Xiao J, Wu G, Wang L, Kovalik ME, Chryst-Stangl M, Davis EE, et al. The Human FSGS-Causing ANLN R431C Mutation Induces Dysregulated PI3K/AKT/mTOR/Rac1 Signaling in Podocytes. J Am Soc Nephrol. 2018;29(8):2110–22. https://doi.org/10.1681/asn.2017121338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Oegema K, Savoian MS, Mitchison TJ, Field CM. Functional analysis of a human homologue of the Drosophila actin binding protein anillin suggests a role in cytokinesis. J Cell Biol. 2000;150(3):539–52. https://doi.org/10.1083/jcb.150.3.539.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang Z, Chen J, Zhong MZ, Huang J, Hu YP, Feng DY, Zhou ZJ, Luo X, Liu ZQ, Jiang WZ, et al. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients. Cancer Chemother Pharmacol. 2017;79(3):535–43. https://doi.org/10.1007/s00280-017-3248-2.

    Article  CAS  PubMed  Google Scholar 

  10. Wang A, Dai H, Gong Y, Zhang C, Shu J, Luo Y, Jiang Y, Liu W, Bie P. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. J Exp Clin Cancer Res. 2019;38(1):347. https://doi.org/10.1186/s13046-019-1340-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008;14(15):4794–9. https://doi.org/10.1158/1078-0432.Ccr-08-0576.

    Article  CAS  PubMed  Google Scholar 

  12. Jia H, Gao Z, Yu F, Guo H, Li B. Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice. Exp Ther Med. 2021;21(5):454. https://doi.org/10.3892/etm.2021.9885.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:6352. https://doi.org/10.1126/science.aan2507.

    Article  CAS  Google Scholar 

  14. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER20 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(1):W509–14. https://doi.org/10.1093/nar/gkaa407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60. https://doi.org/10.1093/nar/gkz430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10(1):5679. https://doi.org/10.1038/s41467-019-13528-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Barakat A, Mittal A, Ricketts D, Rogers BA. Understanding survival analysis: actuarial life tables and the Kaplan-Meier plot. Br J Hosp Med. 2019;80(11):642–6. https://doi.org/10.12968/hmed.2019.80.11.642.

    Article  Google Scholar 

  18. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signaling. 2013;6(269):1. https://doi.org/10.1126/scisignal.2004088.

    Article  CAS  Google Scholar 

  19. Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinf. 2014;15(1):293. https://doi.org/10.1186/1471-2105-15-293.

    Article  Google Scholar 

  20. Chen RQ, Yang QK, Lu BW, Yi W, Cantin G, Chen YL, Fearns C, Yates JR 3rd, Lee JD. CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res. 2009;69(6):2663–8. https://doi.org/10.1158/0008-5472.Can-08-3222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, Ong SE, Gammeltoft S, Carr SA, Yaffe MB. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J. 2007;26(9):2262–73. https://doi.org/10.1038/sj.emboj.7601683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villén J, Li J, Cohn MA, Cantley LC, Gygi SP. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A. 2004;101(33):12130–5. https://doi.org/10.1073/pnas.0404720101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dephoure N, Zhou C, Villén J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008;105(31):10762–7. https://doi.org/10.1073/pnas.0805139105.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Domingues P, González-Tablas M, Otero Á, Pascual D, Miranda D, Ruiz L, Sousa P, Ciudad J, Gonçalves JM, Lopes MC, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1–15. https://doi.org/10.1016/j.bbi.2015.07.019.

    Article  CAS  PubMed  Google Scholar 

  25. Steven A, Seliger B. The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Breast Care. 2018;13(1):16–21. https://doi.org/10.1159/000486585.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18(2):99–115. https://doi.org/10.1038/s41573-018-0004-1.

    Article  CAS  PubMed  Google Scholar 

  27. Piekny AJ, Maddox AS. The myriad roles of Anillin during cytokinesis. Cell Dev Biol. 2010;21(9):881–91. https://doi.org/10.1016/j.semcdb.2010.08.002.

    Article  CAS  Google Scholar 

  28. Tuan NM, Lee CH. Role of anillin in tumour: from a prognostic biomarker to a novel target. Cancers. 2020;12(6):1600. https://doi.org/10.3390/cancers12061600.

    Article  CAS  PubMed Central  Google Scholar 

  29. Zhou W, Wang Z, Shen N, Pi W, Jiang W, Huang J, Hu Y, Li X, Sun L. Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer. Mol Cell Biochem. 2015;398(1–2):11–9. https://doi.org/10.1007/s11010-014-2200-6.

    Article  CAS  PubMed  Google Scholar 

  30. Pandi NS, Manimuthu M, Harunipriya P, Murugesan M, Asha GV, Rajendran S. In silico analysis of expression pattern of a Wnt/β-catenin responsive gene ANLN in gastric cancer. Gene. 2014;545(1):23–9. https://doi.org/10.1016/j.gene.2014.05.013.

    Article  CAS  PubMed  Google Scholar 

  31. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371-385.e318. https://doi.org/10.1016/j.cell.2018.02.060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557–65. https://doi.org/10.1001/jama.2011.1456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cha S, Lee E, Won HH. Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites. NPJ breast cancer. 2021;7(1):93. https://doi.org/10.1038/s41523-021-00303-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64. https://doi.org/10.1186/s13059-015-0620-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ju Q, Li X, Zhang H, Yan S, Li Y, Zhao Y. NFE2L2 Is a potential prognostic biomarker and is correlated with immune infiltration in brain lower grade glioma: a pan-cancer analysis. Oxid Med Cell Longevity. 2020;2020:3580719. https://doi.org/10.1155/2020/3580719.

    Article  CAS  Google Scholar 

  36. Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J, Ouakrim H, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115(17):E4041–50. https://doi.org/10.1073/pnas.1720948115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9(1):1591. https://doi.org/10.1038/s41467-018-03900-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70. https://doi.org/10.1186/s12943-019-0994-2.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M, Palomo-Ponce S, Tauriello DV, Byrom D, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320–9. https://doi.org/10.1038/ng.3225.

    Article  CAS  PubMed  Google Scholar 

  40. Watkins LR, Orlandi C. Orphan G Protein Coupled Receptors in Affective Disorders. Genes. 2020;11:6. https://doi.org/10.3390/genes11060694.

    Article  CAS  Google Scholar 

  41. Schnaar RL, Lopez PH. Myelin-associated glycoprotein and its axonal receptors. J Neurosci Res. 2009;87(15):3267–76. https://doi.org/10.1002/jnr.21992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cloake NC, Yan J, Aminian A, Pender MP, Greer JM. PLP1 Mutations in Patients with Multiple Sclerosis: Identification of a New Mutation and Potential Pathogenicity of the Mutations. J Neurosci Res. 2018;7:10. https://doi.org/10.3390/jcm7100342.

    Article  CAS  Google Scholar 

  43. Yang XM, Cao XY, He P, Li J, Feng MX, Zhang YL, Zhang XL, Wang YH, Yang Q, Zhu L, et al. Overexpression of Rac GTPase Activating Protein 1 contributes to proliferation of cancer cells by reducing hippo signaling to promote cytokinesis. Gastroenterology. 2018;155(4):1233-1249.e1222. https://doi.org/10.1053/j.gastro.2018.07.010.

    Article  CAS  PubMed  Google Scholar 

  44. Imaoka H, Toiyama Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Inoue Y, Mohri Y, et al. RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2015;36(3):346–54. https://doi.org/10.1093/carcin/bgu327.

    Article  CAS  PubMed  Google Scholar 

  45. Kamijo K, Ohara N, Abe M, Uchimura T, Hosoya H, Lee JS, Miki T. Dissecting the role of Rho-mediated signaling in contractile ring formation. Mol Biol Cell. 2006;17(1):43–55. https://doi.org/10.1091/mbc.e05-06-0569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Nishimura Y, Yonemura S. Centralspindlin regulates ECT2 and RhoA accumulation at the equatorial cortex during cytokinesis. J Cell Sci. 2006;119(Pt 1):104–14. https://doi.org/10.1242/jcs.02737.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

None.

Author information

Author notes

  1. Yanlong Shi, Xinyu Ma, Menglu Wang, Sheng Lan and Haokun Jian have contributed equally to this work and share first authorship

Authors and Affiliations

  1. Department of General Surgery, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, Anhui, China

    Yanlong Shi

  2. Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China

    Xinyu Ma, Menglu Wang & Fei Zhong

  3. The Second Clinical College Clinical Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China

    Sheng Lan

  4. School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China

    Haokun Jian

  5. Department of Pathology, Anhui Medical University, Hefei, Anhui, China

    Yue Wang

  6. School of Nursing, Anhui Medical University, HeFei, Anhui, China

    Qian Wei

Authors
  1. Yanlong Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyu Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Menglu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sheng Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haokun Jian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qian Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fei Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YLS, XYM and MLW designed the study. XYM, SL and HKJ drafted the manuscript. YLS revised the manuscript. YLS, MLW, QW and YW performed the experiments. YLS, FZ and QW provided Conceptualization and Methodology. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Fei Zhong.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1.

Meta analysis on the ANLN expression difference between normal tumor and tumor using the Oncomine. A Cervical cancer. B Head and neck cancer. C Colorectal cancer. D Breast cancer. E Gastric cancer.

Additional file 2: Fig. S2.

Expression of ANLN in different pathological stages across cancers. A CESC, DLBC, COAD, CHOL. B ESCA, HNSC, LUSC, OV. C PAAD, READ, THCA, UCEC. D STAD, SKCM, UCS, TGCT.

Additional file 3: Fig. S3.

The correlation analysis between ANLN expression and prognosis of cancers in TCGA database using GEPIA2. A Overall survival. B Disease-free survival.

Additional file 4: Fig. S4.

Analysis of the correlation between ANLN expression and immune cells. A CD4+T cells. B CD8+T cells.

Additional file 5: Fig. S5.

Analysis of the correlation between ANLN expression and immune cells. A Macrophage. B NK cells.

Additional file 6: Fig. S6.

Analysis of the correlation between ANLN expression and immune cells. A B cells. B Neutrophils.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shi, Y., Ma, X., Wang, M. et al. Comprehensive analyses reveal the carcinogenic and immunological roles of ANLN in human cancers. Cancer Cell Int 22, 188 (2022). https://doi.org/10.1186/s12935-022-02610-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-022-02610-1

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us